Immunome (NASDAQ:IMNM) Sets New 12-Month Low - Should You Sell?

Immunome logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Immunome shares hit a new 52-week low of $16.38, below the previous close of $16.61; the stock’s 50-day and 200-day moving averages were $19.92 and $22.07.
  • Analyst views are mostly positive: 14 analysts rate the stock Buy, one Hold, and one Sell, with a consensus “Moderate Buy” rating and a $33.85 price target.
  • The company reported a quarterly loss of $0.76 per share, missing analyst expectations of a $0.62 loss per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) shares reached a new 52-week low on Friday. The stock traded as low as $16.38 and last traded at $16.3930, with a volume of 561 shares traded. The stock had previously closed at $16.61.

Analyst Upgrades and Downgrades

IMNM has been the topic of several analyst reports. Truist Financial lifted their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Stifel Nicolaus reduced their price target on shares of Immunome from $24.00 to $23.00 and set a "hold" rating for the company in a research report on Tuesday, November 10th. Alliance Global Partners assumed coverage on shares of Immunome in a research note on Monday, September 21st. They issued a "buy" rating and a $32.00 price objective for the company. William Blair started coverage on shares of Immunome in a research report on Friday, October 16th. They set an "outperform" rating on the stock. Finally, Wall Street Zen downgraded shares of Immunome from a "sell" rating to a "strong sell" rating in a research note on Sunday, October 4th. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Immunome has an average rating of "Moderate Buy" and a consensus price target of $33.85.

Read Our Latest Research Report on Immunome

Immunome Trading Up 0.1%

The stock has a fifty day simple moving average of $19.92 and a 200-day simple moving average of $22.07. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -6.26 and a beta of 2.68.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.14). Sell-side analysts forecast that Immunome, Inc. will post -2.64 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jack Higgins sold 13,200 shares of the company's stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company's stock.

Institutional Investors Weigh In On Immunome

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Immunome during the 2nd quarter worth about $186,588,000. Primecap Management Co. CA bought a new stake in Immunome in the second quarter valued at about $97,081,000. Bank of America Corp DE bought a new stake in Immunome in the second quarter valued at about $13,729,000. Parkman Healthcare Partners LLC acquired a new position in Immunome in the second quarter worth about $12,591,000. Finally, Wellington Management Group LLP raised its position in Immunome by 10.1% in the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company's stock worth $110,404,000 after purchasing an additional 478,239 shares in the last quarter. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

(Get Free Report)

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company's research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunome Right Now?

Before you consider Immunome, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.

While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines